ImmunoGen, Inc. Reports First Quarter Fiscal Year 2007 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced financial results for the three-month period ended September 30, 2006 – the first quarter of the Company’s 2007 fiscal year.

Back to news